Ibrutinib

Ibrutinib (brand name Imbruvica) is a medication used primarily to treat certain types of cancers, particularly blood cancers like chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). It is classified as a Bruton tyrosine kinase (BTK) inhibitor, which works by interfering with signals that promote the growth of cancer cells.